Cingulate Inc. (CING)
Market Closed
14 Sep, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
5. 17
+0.15
+2.988%
$
69.9M Market Cap
- P/E Ratio
- Div Yield
101,144 Volume
-3.21 Eps
$ 5.02
Previous Close Investors:
Want to track CING and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Cingulate stock surges 115% after European patent approval for ADHD treatment: Is it a buy?
Cingulate Inc (NASDAQ: CING), a biopharmaceutical firm specializing in innovative ADHD treatments, experienced a remarkable surge in its stock price on Friday, with shares skyrocketing by 115%. This dramatic increase is attributed to the company's recent achievement of securing a European patent for CTx-1301, its flagship ADHD treatment.
Invezz | 2 years ago
